CN1069540C - preparation process of compound red sage tablet - Google Patents
preparation process of compound red sage tablet Download PDFInfo
- Publication number
- CN1069540C CN1069540C CN 99111781 CN99111781A CN1069540C CN 1069540 C CN1069540 C CN 1069540C CN 99111781 CN99111781 CN 99111781 CN 99111781 A CN99111781 A CN 99111781A CN 1069540 C CN1069540 C CN 1069540C
- Authority
- CN
- China
- Prior art keywords
- red sage
- sage root
- salviae miltiorrhizae
- radix notoginseng
- radix salviae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 240000007164 Salvia officinalis Species 0.000 title claims abstract description 21
- 235000005412 red sage Nutrition 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims abstract description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 9
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 9
- 239000000706 filtrate Substances 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 5
- 238000005469 granulation Methods 0.000 claims abstract description 5
- 230000003179 granulation Effects 0.000 claims abstract description 5
- 238000009495 sugar coating Methods 0.000 claims abstract description 5
- 238000003809 water extraction Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 24
- 239000008899 fufang danshen Substances 0.000 description 15
- 229960003371 protocatechualdehyde Drugs 0.000 description 12
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 11
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 11
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 11
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 10
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 10
- 235000017276 Salvia Nutrition 0.000 description 10
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 4
- 229930183118 Tanshinone Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a novel technology for preparing compound red sage root tablets. The technology comprises: 1. red sage roots are added in ethanol to be soaked and filtered after pulverized, a small amount of filtrate is recovered by decompressing, appropriate powdered radix notoginseng or auxiliary materials are added for granulation and are quickly dired under low temperature, and the components are preserved in a closed container; 2. residues is extracted by water for two times after the residues are treated by alkaline liquor, water extraction liquor is merged, concentrated, sprayed and dried, and dry red sage root paste is obtained; 3. mixed granulation and dryness are carried out to the dry red sage root paste and residual powdered radix notoginseng or appropriate auxiliary materials; 4. granules in the procedure 1, granules in the procedure 3 and comminuted borneol are mixed evenly, and finished products are obtained in a tabletting sugar coating method. The present invention has the advantages of good therapeutic efficacy, low cost and resource saving, and the content of effective components in the prepared red sage root tablets is improved greatly.
Description
The present invention relates to a kind of preparation process of compound red sage tablet.
FUFANG DANSHEN PIAN is that Chinese Pharmacopoeia is gone through the kind that version is recorded, the effect of tool blood circulation promoting and blood stasis dispelling, regulating QI to relieve pain.Be used for feeling oppressed in the heart, angina pectoris, be medicine at present commonly used clinically.Its traditional handicraft is:
1, get Radix Salviae Miltiorrhizae and extract three times, add alcohol reflux for the first time and filtered in 1.5 hours, filtrate recycling ethanol, being concentrated into relative density is 1.30 (55-60 ℃).
2, add 50% alcohol reflux for the second time filtered in 1.5 hours.Add water for the third time and refluxed 2 hours, filter, merge second and third time filtrate, reclaim ethanol, being concentrated into relative density is 1.40 (55-60 ℃), and with the concentrated solution merging first time, mixing, making relative density is 1.35-1.39 (55-60 ℃) extractum, promptly.
3, Radix Notoginseng powder is broken into fine powder and Radix Salviae Miltiorrhizae extractum is mixed thoroughly, drying is made granule.
4, with the Borneolum Syntheticum porphyrize, with above-mentioned granule mixing, tabletting, sugar coating promptly.
The shortcoming of above-mentioned technology is active ingredient tanshinone IIA, danshensu and protocatechualdehyde contained in the Radix Salviae Miltiorrhizae can not to be extracted effectively.According to document 1 (West China pharmaceutical journal 1996,11 (4) 213-215) report, in 7 reply side's Radix Salviae Miltiorrhizae Tabellae samples of its investigation, the high-load of every of tanshinone IIA is 0.0918mg, and minimum content is 0.0016mg.The applicant also measures the contained tanshinone IIA of FUFANG DANSHEN PIAN sample, danshensu and protocatechualdehyde that 7 tame pharmaceutical factories produce, measurement result shows, the FUFANG DANSHEN PIAN in 90% pharmaceutical factory only contains the tanshinone IIA of trace, even 60% sample do not detect the tanshinone IIA peak, and the content of danshensu and protocatechualdehyde also seldom (is seen attached list and accompanying drawing 1-10).
The objective of the invention is at above-mentioned shortcoming of the prior art, and provide a kind of its active ingredient tanshinone IIA, danshensu and protocatechualdehyde content preparation process of compound red sage tablet high, that therapeutic effect is good.
The objective of the invention is to be achieved through the following technical solutions:
Preparation process of compound red sage tablet is:
A, get Radix Salviae Miltiorrhizae and carry out coarse pulverization, add soak with ethanol 4-8 hour, filter, filtrate decompression be recycled to a small amount of after, add an amount of Radix Notoginseng powder or adjuvant and granulate, low temperature is dry rapidly, preserves standby in the hermetic container;
B, residue are used water extraction 2 times after handling with alkali liquor, and temperature is 80-100 ℃, merges aqueous extract, and concentrated, spray drying get the dried cream of Radix Salviae Miltiorrhizae;
C, get the dried cream of Radix Salviae Miltiorrhizae and remaining Radix Notoginseng powder and appropriate amount of auxiliary materials, mixing granulation, 60-70 ℃ of drying;
D, with the granule under granule under the A item and the C item and the Borneolum Syntheticum of porphyrize, mix homogeneously, tabletting sugar coating are promptly.
Principle of the present invention is as follows:
Tanshinone IIA is to reach the position that exists according to its case of thermal instability in medical material, has designed and its overwhelming majority can have been carried to the greatest extent, avoids few extracting method that contacts with thermal source again.
Danshensu and protocatechualdehyde be according to it for weakly acidic material, be soluble in the alkali salify, increased the character that chemical compound tends towards stability behind dissolubility in its water and the salify, formulated rational novel technology for extracting.
Advantage of the present invention is as follows:
1, adopt the content of tanshinone IIA, danshensu and protocatechualdehyde in the FUFANG DANSHEN PIAN that the present invention produced to improve greatly.The content of tanshinone IIA, be 11 times of maximum content of document 1 report, 608 times of minimum content, be the 2.6-49 doubly (wherein 5 batch samples do not detect the tanshinone IIA peak) of 7 batch samples measured of applicant, danshensu is 7-39.9 a times of institute's test sample product, protocatechualdehyde is 14-250 doubly (for details see attached table reaching accompanying drawing 1-10), has broken through forefathers' record, has founded new record.
2, effectively utilized the effective ingredient in the red rooted salvia, the great deal of raw materials and the energy have been saved, the pharmaceutical factory of the whole nation tens families last hundred tame production FUFANG DANSHEN PIAN, if obtain through refining production by traditional handicraft, be the content that at all can't reach present new technology, both just medical materials of throwing several times to tens times, also difficulty is produced satisfactory product more.The resource 90% of red rooted salvia has been wasted.The present invention can be the RMB of country's saving several ten million and even more than one hundred million units.
3, to have a therapeutic effect good for the FUFANG DANSHEN PIAN produced of the present invention, the characteristics that cost is low, and therapeutic effect will improve several times to tens of times.
Embodiments of the invention are as follows:
A, get Radix Salviae Miltiorrhizae and carry out coarse pulverization, add soak with ethanol 4-8 hour, filter, filtrate decompression be recycled to a small amount of after, add an amount of Radix Notoginseng powder or adjuvant and granulate, low temperature is dry rapidly, preserves standby in the hermetic container;
B, residue are used water extraction 2 times after handling with alkali liquor, and temperature is 80-100 ℃, merges aqueous extract, and concentrated, spray drying get the dried cream of Radix Salviae Miltiorrhizae;
C, get the dried cream of Radix Salviae Miltiorrhizae and remaining Radix Notoginseng powder and appropriate amount of auxiliary materials, mixing granulation, 60-70 ℃ of drying;
D, with the granule under granule under the A item and the C item and the Borneolum Syntheticum of porphyrize, mix homogeneously, the tabletting sugar coating promptly.
Subordinate list: TANSHINONES II in the FUFANG DANSHEN PIAN
A, the examination of danshensu, protocatechualdehyde content
| Factory's name | Lot number | The TANSHINONES II AAmount mg/ sheet | Product of the present invention is its multiple | Protocatechualdehyde amount mg/ sheet | Product of the present invention is its multiple | Danshensu (in protocatechualdehyde) mg/ sheet | Product of the present invention is its multiple |
| Product of the present invention | 990719 | 1.01 | 1.65 | 2.67 | |||
| Product of the present invention | 990720 | 1.02 | 1.99 | 2.74 | |||
| White Cloud Mountain pharmacy head factory | 980305-607 | Do not detect | No several times | 0.096 | 17.2 | 0.21 | 12.7 |
| White Cloud Mountain pharmacy head factory | 940402602 | Do not detect | No several times | 0.071 | 23.2 | 0.148 | 18.0 |
| Flower city pharmaceutical factory, Guangzhou | 940321-4 | Do not detect | No several times | 0.113 | 14.6 | 0.213 | 12.5 |
| Guangdong Longchuan pharmaceutical factory | 950606 | Do not detect | No several times | 0.030 | 55 | 0.126 | 21.2 |
| The military region, Guangdong Longhua pharmaceutical factory | 94-2034 | Do not detect | No several times | 0.054 | 30.6 | 0.225 | 11.9 |
| The Xi'an pharmaceutical factory of traditional Chinese medicine | 920604 | 0.0208 | 48.6 | 0.118 | 14.0 | 0.394 | 6.8 |
| Stone city Hua Long pharmaceutical factory | 990305 | 0.391 | 2.58 | 0.0066 | 250 | 0.067 | 39.9 |
Accompanying drawing and drawing explanation:
Fig. 1 is the mensuration collection of illustrative plates of protocatechualdehyde standard reference material.Concentration: 0.02024mg/ml.
The mensuration collection of illustrative plates of the FUFANG DANSHEN PIAN that Fig. 2 makes for the present invention.Concentration: 7.2mg red rooted salvia/ml.
The mensuration collection of illustrative plates of the FUFANG DANSHEN PIAN that Fig. 3 makes for the present invention.Concentration: 7.2mg red rooted salvia/ml.
Fig. 4 is the mensuration collection of illustrative plates of commercially available FUFANG DANSHEN PIAN (Guangdong Longchuan pharmaceutical factory 950606).Concentration: be equivalent to 20mg red rooted salvia/ml.
Fig. 5 is the mensuration collection of illustrative plates in commercially available FUFANG DANSHEN PIAN (the imperial pharmaceutical factory 990305 of Shijiazhuang China).Concentration: be equivalent to 20mg red rooted salvia/ml.
Fig. 6 is the mensuration collection of illustrative plates of tanshinone IIA standard reference material.Concentration: 0.0177mg/ml.
The mensuration collection of illustrative plates of the FUFANG DANSHEN PIAN that Fig. 7 makes for the present invention.Concentration: be equivalent to 20mg red rooted salvia/ml.
The mensuration collection of illustrative plates of the FUFANG DANSHEN PIAN that Fig. 8 makes for the present invention.Concentration is equivalent to 20mg red rooted salvia/ml.
Fig. 9 is the mensuration collection of illustrative plates of commercially available FUFANG DANSHEN PIAN (940402-60 of Chinese Traditional Medicine Factory of Baiyunshan Pharmaceutical Gneral Factory 2).Concentration: be equivalent to 20mg red rooted salvia/ml.
Figure 10 is the mensuration collection of illustrative plates of commercially available FUFANG DANSHEN PIAN (the Xi'an pharmaceutical factory of traditional Chinese medicine 920604).Concentration: be equivalent to 20mg red rooted salvia/ml.
Peak 1 is a danshensu in the accompanying drawing; Peak 2 is a protocatechualdehyde; Peak 3 is the TANSHINONES II
A
Claims (1)
1, preparation process of compound red sage tablet is characterized in that:
A, get Radix Salviae Miltiorrhizae and carry out coarse pulverization, add soak with ethanol 4-8 hour, filter, filtrate decompression be recycled to a small amount of after, add an amount of Radix Notoginseng powder or adjuvant and granulate, low temperature is dry rapidly, preserves standby in the hermetic container;
B, residue are used water extraction 2 times after handling with alkali liquor, and temperature is 80-100 ℃, merges aqueous extract, and concentrated, spray drying get the dried cream of Radix Salviae Miltiorrhizae;
C, get the dried cream of Radix Salviae Miltiorrhizae and remaining Radix Notoginseng powder and appropriate amount of auxiliary materials, mixing granulation, 60-70 ℃ of drying;
D, with the granule under granule under the A item and the C item and the Borneolum Syntheticum of porphyrize, mix homogeneously, the tabletting sugar coating promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99111781 CN1069540C (en) | 1999-08-11 | 1999-08-11 | preparation process of compound red sage tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 99111781 CN1069540C (en) | 1999-08-11 | 1999-08-11 | preparation process of compound red sage tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1249943A CN1249943A (en) | 2000-04-12 |
| CN1069540C true CN1069540C (en) | 2001-08-15 |
Family
ID=5275298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 99111781 Expired - Fee Related CN1069540C (en) | 1999-08-11 | 1999-08-11 | preparation process of compound red sage tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1069540C (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486464B2 (en) | 2000-12-22 | 2013-07-16 | Tasly Pharmaceutical Group Co. Ltd. | Herbal composition for angina pectoris, method to prepare same and uses thereof |
| BRPI0116589B1 (en) * | 2000-12-22 | 2018-07-03 | Tasly Pharmaceutical Group Co., Ltd. | HERBAL COMPOSITION FOR ANGINA PECTORIS, METHOD FOR PREPARING IT AND USING THIS |
| CN1319519C (en) * | 2002-12-23 | 2007-06-06 | 北京采瑞医药有限公司 | Composite red sage root spray for cardio-cerebral diseases and its preparing method |
| CN1319521C (en) * | 2002-12-23 | 2007-06-06 | 北京采瑞医药有限公司 | Composite red sage root granules for cardio-cerebral diseases and its preparing method |
| US20050037094A1 (en) | 2003-07-31 | 2005-02-17 | Xijun Yan | Composition for heart disease, its active ingredients, method to prepare same and uses thereof |
| CN100404041C (en) * | 2004-06-30 | 2008-07-23 | 天津天士力制药股份有限公司 | Medicinal composition for treating coronary heart disease |
| JP5288667B1 (en) * | 2012-02-28 | 2013-09-11 | 建国 顧 | Healthy tea and method for producing the same |
| CN102613556A (en) * | 2012-03-31 | 2012-08-01 | 东北林业大学 | Production process for water-soluble full valence powder of medicinal and edible materials and new resource foods |
-
1999
- 1999-08-11 CN CN 99111781 patent/CN1069540C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1249943A (en) | 2000-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1069540C (en) | preparation process of compound red sage tablet | |
| CN1686421A (en) | Black fruit lycium plant fruit extract, its preparation method and application | |
| CN102526190A (en) | Production method and application of high-quality stable red-rooted salvia medicinal material | |
| CN100560090C (en) | A kind of preparation method of obtaining total tanshinone and total phenolic acid step by step | |
| CN114712475B (en) | Dai medicine composition for preventing and/or treating reperfusion injury after myocardial ischemia and preparation method and application thereof | |
| CN100339096C (en) | Preparation of 'Xin Ke Shu' tablet for treating coronary heart disease | |
| CN1270740C (en) | Ready prepared Chinese medicine for treating angeitis and preparation process | |
| CN1301707C (en) | Danhong freeze dried powder injection agent and its preparation method | |
| CN1072012C (en) | New process for extracting danshensu from red sage root and protocatechualdehyde | |
| CN1907429A (en) | Method for preparing and controlling the quality of Chinese medicinal soft capsule | |
| CN1876009A (en) | Hemostatic notoginseng chewing tablet and preparation method thereof | |
| CN1927293A (en) | Chinese medicine composition for treating skin burn and scald | |
| CN1456236A (en) | Preparation of woman effervescent tablets | |
| CN1562239A (en) | Lingdancao dispersion tablet and preparation method | |
| CN1456229A (en) | Preparation of donkey hide gelatin effervescent granules for nourishing blood | |
| CN1682971A (en) | Compound isatis root freeze-dried powder injection and its preparing method | |
| CN101411748B (en) | Salvia root total phenolic acid tablet and preparation method thereof | |
| CN1850171A (en) | Method for preparing rhubarb formula granules | |
| CN101700327A (en) | Drug for treating prostatitis and preparation method | |
| CN1879849A (en) | Compound capsule with pseudo-ginseng and Chinese fanpalm seed, its preparation process and quality control method | |
| CN1850239A (en) | Vitamin C and Lonicera and Forsythia capsule | |
| CN1631414A (en) | Medicinal capsule for treating gynecological inflammation and its preparation process | |
| CN1562249A (en) | Jingangteng dispersion tablet and preparation method | |
| CN101485777B (en) | Method for producing medicament composition for tonifying blood | |
| CN119424345A (en) | Preparation method of Danggui Buxue granules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHOU YU Free format text: FORMER OWNER: HEBEI PROVINCE INSTITUTE FOR DRUG CONTROL Effective date: 20051118 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20051118 Address after: 071000 No. 419 North Street, the Great Wall, Hebei, Baoding Patentee after: Zhou Yu Address before: 050011, 44 prosperous prosperous street, Hebei, Shijiazhuang Patentee before: Drug Control Institute |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20010815 Termination date: 20150811 |
|
| EXPY | Termination of patent right or utility model |